MX9604024A - Virus recombinante, preparacion y utilizacion en terapia genica. - Google Patents

Virus recombinante, preparacion y utilizacion en terapia genica.

Info

Publication number
MX9604024A
MX9604024A MX9604024A MX9604024A MX9604024A MX 9604024 A MX9604024 A MX 9604024A MX 9604024 A MX9604024 A MX 9604024A MX 9604024 A MX9604024 A MX 9604024A MX 9604024 A MX9604024 A MX 9604024A
Authority
MX
Mexico
Prior art keywords
gdnf
glial
neurotrophic factor
derived neurotrophic
recombinant adenoviruses
Prior art date
Application number
MX9604024A
Other languages
English (en)
Inventor
Philippe Horellou
Jacques Mallet
Michel Perricaudet
Frederic Revah
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MX9604024A publication Critical patent/MX9604024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a los adenovirus recombinantes que poseen una secuencia de ADN heterologo que codifica para el factor neurotrofico derivado de células Gliales (GDNF), a su preparacion, a su utilizacion para tratamiento y/o a al prevencion de enfermedades neurodegenerativas.
MX9604024A 1994-03-25 1995-03-23 Virus recombinante, preparacion y utilizacion en terapia genica. MX9604024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403542A FR2717824B1 (fr) 1994-03-25 1994-03-25 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000356 WO1995026408A1 (fr) 1994-03-25 1995-03-23 Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf)

Publications (1)

Publication Number Publication Date
MX9604024A true MX9604024A (es) 1997-09-30

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9604024A MX9604024A (es) 1994-03-25 1995-03-23 Virus recombinante, preparacion y utilizacion en terapia genica.

Country Status (14)

Country Link
US (1) US6245330B1 (es)
EP (1) EP0752004B1 (es)
JP (1) JPH09510620A (es)
KR (1) KR100403707B1 (es)
AT (1) ATE335832T1 (es)
AU (1) AU704910B2 (es)
CA (1) CA2184841C (es)
DE (1) DE69535155T2 (es)
FI (1) FI963805A (es)
FR (1) FR2717824B1 (es)
IL (1) IL113109A0 (es)
MX (1) MX9604024A (es)
WO (1) WO1995026408A1 (es)
ZA (1) ZA952433B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
WO1998046737A2 (en) * 1997-04-15 1998-10-22 University Of Medicine And Dentistry Of New Jersey cDNA FOR HUMAN GDNF AND PROMOTER THEREFOR WHICH ALLOWS REGULATED AND CONSTITUTIVE EXPRESSION
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
NZ533833A (en) 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
CA2550459C (en) * 2003-12-18 2009-12-15 Biomas, Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
ES2618787T5 (es) 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
CA2690815A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
EP2315833B8 (en) 2008-05-20 2015-05-27 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US20140259192A1 (en) 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FI963805A0 (fi) 1996-09-24
DE69535155T2 (de) 2007-06-28
EP0752004A1 (fr) 1997-01-08
DE69535155D1 (de) 2006-09-21
JPH09510620A (ja) 1997-10-28
CA2184841C (fr) 2009-08-18
ATE335832T1 (de) 2006-09-15
FI963805A (fi) 1996-09-24
FR2717824A1 (fr) 1995-09-29
IL113109A0 (en) 1995-06-29
AU704910B2 (en) 1999-05-06
ZA952433B (en) 1996-01-15
CA2184841A1 (fr) 1995-10-05
EP0752004B1 (fr) 2006-08-09
KR970702373A (ko) 1997-05-13
KR100403707B1 (ko) 2004-02-11
WO1995026408A1 (fr) 1995-10-05
FR2717824B1 (fr) 1996-04-26
US6245330B1 (en) 2001-06-12
AU2141195A (en) 1995-10-17

Similar Documents

Publication Publication Date Title
MX9604024A (es) Virus recombinante, preparacion y utilizacion en terapia genica.
HK1022480A1 (en) Porcine factor viii and hybrids thereof
AU8147294A (en) Recombinant viruses coding for thymidine kinase in gene therapy
GB2269753B (en) Surgical implants, primarily for spine stabilization
AU2142595A (en) Recombinant adenoviruses coding for basic fibroblast growth factors (bfgf)
GR3032628T3 (en) NEW GROWTH/DIFFERENTIATION FACTOR OF THE TGF--g(b) FAMILY
AU630950B2 (en) Fibronectin binding protein as well as its preparation
AU2319497A (en) Helper-free, totally defective adenovirus for gene therapy
EP0626402A3 (en) Process for the preparation of linear monofunctional and difunctional telechelic polymers and compositions thus obtained.
EP0764082A4 (en) ODOR COMPOSITION, METHOD AND METHOD FOR RELEASE
AU1235392A (en) Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
PT870046E (pt) Vacina viva recombinante à base de herpesvírus felino de tipo 1, especialmente contra a peritonite infecciosa felina
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
ZA979573B (en) (Alpha-aminophosphino) peptide derivatives, process for their preparation and their therapeutic applications.
AU3733497A (en) Recombinant sef14 fimbrial protein from salmonella
HUT64369A (en) Collagen binding protein and method for producing it
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
MX9603490A (es) Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf).
AU2820992A (en) Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
HUP9904413A3 (en) Purified proteins, recombinant dna sequences and processes for controlling the ripening of coffee plants
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
AU3694795A (en) Novel oligomers, process for their preparation and methods for their use
AU2004595A (en) Process for preparing recombinant aprotinin and recombinant aprotinin variants having the natural N-terminal sequence
IL116634A0 (en) Solventles process for making 2,6-difluorobenzonitrile
AU5502299A (en) A novel human lysozyme gene, its encoding polypeptide and the method preparing for them